HYBIO(SZ:300199) Zheng Quan Shi Bao Wang·2026-01-15 12:18Core Viewpoint - Han Yu Pharmaceutical has signed a significant sales order for GLP-1 raw materials worth 180 million RMB, which is expected to positively impact the company's annual performance, accounting for 30.50% of the audited revenue for 2024 [1] Group 1: Sales Order and Financial Impact - The company has entered into a sales order with a total procurement amount of 180 million RMB for GLP-1 raw materials [1] - This order represents 30.50% of the company's audited revenue for 2024, indicating a substantial contribution to future earnings [1] - The company has a history of similar transactions with the counterpart, totaling 75.955 million RMB over the past three years [1] Group 2: Business Performance and Capacity Expansion - In the first three quarters of 2025, the company achieved a revenue of 683 million RMB, reflecting a year-on-year growth of 82.06% [2] - The net profit attributable to shareholders for the same period was 71.3515 million RMB, showing a significant increase of 305.00% year-on-year [2] - The company has sufficient orders on hand, and some new production lines have commenced operations this month, enhancing its capacity for high-value intermediates and raw materials [2]